Drugs / licaminlimab
licaminlimab
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT05896670 | Nov 2023 → Mar 2024 | dry eye syndrome | Oculis | Completed | No outcome recorded |
| Phase 2 | NCT02482129 | Jul 2015 → Mar 2016 | anterior uveitis | Alcon Research | Completed | No outcome recorded |
| Phase 2 | NCT02365519 | Mar → Oct 2015 | dry eye syndrome | Alcon, a Novartis Company | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07548632 | Apr → Dec 2026 expected | dry eye syndrome | Oculis | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-06-09 | Oculis | Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease oculis.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | licaminlimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07548632 ↗ |
| Known as | ESBA-1622 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095490 ↗ |
| Known as | LME636 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02365519 ↗ |
| Known as | OCS-02 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095490 ↗ |
| Known as | SS2X3Y9DGM | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095490 ↗ |
| Modality | Monoclonal antibody | — CHEMBL5095490 ↗ |
| Route | Topical | “administered topically in each eye 3 times a day (TID) for 6 weeks” NCT02365519 ↗ |